DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 214 filers reported holding DENALI THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,355 | -22.7% | 64,210 | +7.4% | 0.00% | -25.0% |
Q2 2023 | $1,753 | +32.4% | 59,800 | 0.0% | 0.00% | +33.3% |
Q1 2023 | $1,324 | -20.9% | 59,800 | 0.0% | 0.00% | -25.0% |
Q4 2022 | $1,673 | -99.9% | 59,800 | 0.0% | 0.00% | -20.0% |
Q3 2022 | $1,737,000 | +1.5% | 59,800 | 0.0% | 0.01% | 0.0% |
Q2 2022 | $1,711,000 | -11.7% | 59,800 | 0.0% | 0.01% | 0.0% |
Q1 2022 | $1,938,000 | -18.3% | 59,800 | +9.9% | 0.01% | -16.7% |
Q4 2021 | $2,372,000 | -9.2% | 54,400 | +2.8% | 0.01% | -14.3% |
Q3 2021 | $2,612,000 | -35.2% | 52,900 | 0.0% | 0.01% | -41.7% |
Q2 2021 | $4,032,000 | +93.6% | 52,900 | +39.6% | 0.01% | +71.4% |
Q1 2021 | $2,083,000 | -35.2% | 37,900 | 0.0% | 0.01% | -41.7% |
Q4 2020 | $3,216,000 | +152.0% | 37,900 | +5.9% | 0.01% | +100.0% |
Q3 2020 | $1,276,000 | -16.1% | 35,800 | -51.6% | 0.01% | -25.0% |
Q2 2019 | $1,520,000 | – | 74,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 7,460,732 | $219,569,000 | 28.65% |
ARCH Venture Management, LLC | 5,168,749 | $152,116,000 | 18.54% |
Casdin Capital, LLC | 1,500,000 | $44,145,000 | 3.73% |
Flagship Pioneering Inc. | 2,619,968 | $77,106,000 | 2.90% |
Yiheng Capital Management, L.P. | 1,014,684 | $29,862,000 | 1.71% |
SECTORAL ASSET MANAGEMENT INC | 202,100 | $5,948,000 | 1.20% |
GILDER GAGNON HOWE & CO LLC | 1,956,820 | $57,589,000 | 1.03% |
Artal Group S.A. | 600,000 | $17,658,000 | 0.94% |
Temasek Holdings (Private) Ltd | 5,369,487 | $158,024,002 | 0.87% |
BRANDYWINE MANAGERS, LLC | 9,601 | $283,000 | 0.69% |